2-chloro-4-morpholin-4-yl-6-thiomorpholin-4-yl-[1,3,5]triazine | 41492-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2-chloro-4-morpholin-4-yl-6-thiomorpholin-4-yl-[1,3,5]triazine
• 英文别名: 2-Chloro-4-(4-morpholinyl)-6-(4-thiomorpholinyl)-1,3,5-triazine；4-(4-chloro-6-thiomorpholin-4-yl-1,3,5-triazin-2-yl)morpholine
• CAS: 41492-55-1
• 化学式: C₁₁H₁₆ClN₅OS
• mdl: MFCD01239731
• 分子量: 301.8
• InChiKey: QAIKQFQIULCYBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.727
• 拓扑面积：
  79.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  吗啉 、 2-chloro-4-morpholin-4-yl-6-thiomorpholin-4-yl-[1,3,5]triazine 生成 2,4-di-morpholin-4-yl-6-thiomorpholin-4-yl-[1,3,5]triazine
  参考文献：
  名称：

  Zur Kenntnis der Reaktionsf�higkeit alkylsubstituierter Thiomorpholine, 1. Mitt.

  摘要：

  DOI：

  10.1007/bf00911153
• 作为产物：
  描述：

  吗啉 、 2,4-dichloro-6-thiomorpholin-4-yl-[1,3,5]triazine 生成 2-chloro-4-morpholin-4-yl-6-thiomorpholin-4-yl-[1,3,5]triazine
  参考文献：
  名称：

  Zur Kenntnis der Reaktionsf�higkeit alkylsubstituierter Thiomorpholine, 1. Mitt.

  摘要：

  DOI：

  10.1007/bf00911153

文献信息

• Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
  申请人：Piqur Therapeutics AG

  公开号：US10640516B2

  公开（公告）日：2020-05-05

  The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.

  本发明涉及新型磷酸肌醇 3-激酶 (PI3k)、哺乳动物雷帕霉素靶标 (mTOR) 和 PI3k 相关激酶 (PIKKs) 的式 (I) 抑制剂化合物、 其中 X1、X2 和 X3 是 N 或 CH，但条件是 X1、X2 和 X3 中至少有两个是 N；Y 是 N 或 CH，这些化合物可单独使用或与其它治疗剂结合使用，用于治疗由脂质激酶介导的疾病。
• Treatment of skin lesions
  申请人：PIQUR THERAPEUTICS AG

  公开号：US10993947B2

  公开（公告）日：2021-05-04

  The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.

  本发明涉及一种式 (I) 的化合物、 其中 X1、X2 和 X3 相互独立地是 N 或 CH；但条件是 X1、X2 和 X3 中至少有两个是 N； Y 是 N 或 CH W 是 H 或 F；但当 W 是 F 时，X1、X2 和 X3 是 N； R1 和 R2 相互独立 (i) 式（II）的吗啉基 其中箭头表示式（I）中的键；以及 其中 R3 和 R4 相互独立地为 H、任选被一个或两个 OH、C1-C2-氟烷基、C1-C2-烷氧基、C1-C2-烷氧基 C1-C3烷基、CN 或 C(O)O-C1-C2烷基取代的 C1-C3 烷基；或 R3 和 R4 共同形成选自任选被 1 至 4 个 F、-CH2-O-CH2-、-CH2-NH-CH2-或任何结构取代的 C1-C3 烷烯的二价残基-R5R6-。 其中箭头表示式（II）中的键；或 (ii) 选自硫代吗啉基和哌嗪基的饱和 6 元杂环 Z，任选被 1 至 3 个 R7 取代；其中 R7 在每次出现时均独立地为任选被一个或两个 OH、C1-C2 氟烷基、C1-C2 烷氧基 C1-C3 烷基、C3-C6 环烷基取代的 C1-C3 烷基；或两个 R7 取代基共同形成二价残基-R8R9-，该残基选自任选被 1 至 4 个 F、-CH2-O-CH2-或 -O-CH2CH2-O-取代的 C1-C3 烷基； 但 R1 和 R2 中至少有一个是式 II 的吗啉基； 及其原药、代谢物、同系物、溶剂和药学上可接受的盐，用于预防或治疗受试者的皮肤损伤。
• EP3218358B1
  申请人：——

  公开号：EP3218358B1

  公开（公告）日：2021-06-16
• DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES
  申请人：Piqur Therapeutics AG

  公开号：US20190031682A1

  公开（公告）日：2019-01-31

  The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X 1 , X 2 and X 3 are N or CH, with the proviso that at least two of X 1 , X 2 and X 3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
• TREATMENT OF SKIN LESIONS
  申请人：PIQUR THERAPEUTICS AG

  公开号：US20190290653A1

  公开（公告）日：2019-09-26

  The present invention is relates to a compound of formula (I), wherein X 1 , X 2 and X 3 are, independently of each other, N or CH; with the proviso that at least two of X 1 , X 2 and X 3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X 1 , X 2 and X 3 are N; R 1 and R 2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R 3 and R 4 are independently of each other H, C 1 -C 3 alkyl optionally substituted with one or two OH, C 1 -C 2 fluoroalkyl, C 1 -C 2 alkoxy, C 1 -C 2 alkoxyC 1 -C 3 alkyl, CN, or C(O)O—C 1 -C 2 alkyl; or R 3 and R 4 form together a bivalent residue —R 5 R 6 — selected from C 1 -C 3 alkylene optionally substituted with 1 to 4 F, —CH 2 —O—CH 2 —, —CH 2 —NH—CH 2 —, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R 7 ; wherein R 7 is independently at each occurrence C 1 -C 3 alkyl optionally substituted with one or two OH, C 1 -C 2 fluoroalkyl, C 1 -C 2 alkoxyC 1 -C 3 alkyl, C 3 -C 6 cycloalkyl; or two R 7 substituents form together a bivalent residue —R 8 R 9 — selected from C 1 -C 3 alkylene optionally substituted with 1 to 4 F, —CH 2 —O—CH 2 — or —O—CH 2 CH 2 —O—; with the proviso that at least one of R 1 and R 2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.